ライフサイエンスコーパス: IgG1

1 quency, and class switching of GC B cells to IgG1.

2 sing CocH to replace the Fab region of human IgG1.

3 IL-15N72D.IL-15RalphaSu to the Fc domain of IgG1.

4 din and very weak staining for C1q, C4d, and IgG1.

5 serum half-lives as long as wild-type human IgG1.

6 ubclass response, regardless of vaccine, was IgG1.

7 , have a wide range of substrates, including IgG1.

8 quency, and class switching of GC B cells to IgG1.

9 rile gamma1 germ-line transcripts and CSR to IgG1.

10 known crystal structure of full-length human IgG1.

11 lowest increase (1%) through spiked oxidized IgG1.

12 h stability equivalent to that of the parent IgG1.

13 ed cytotoxity in both murine IgG2a and human IgG1.

14 reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG

15 classes having homologous F(ab')2 C termini (IgG1/3/4).

16 with significantly higher AHA levels against IgG1/3/4.

17 tein G to deplete IgG Ab. alpha-Gal-specific IgG1-4 Ab in individuals with and without meat allergy w

18 The distribution of iDSA IgG1-4 subclasses among the population was 75.2%, 44.0%,

19 gM and different subclasses of anti-PEG IgG (IgG1-4) in both contemporary and historical human sample

20 hD IgG Abs of the four different subclasses (IgG1-4) with and without core fucose (i.e., 20% fucose r

21 studied the solution structures of two human IgG1 6a and 19a monoclonal antibodies in different buffe

22 Immunoglobulin G1 (IgG1), a subclass of human serum antibodies, is the most

23 silon directs the early choice of IgE versus IgG1, a key physiological response against parasitic inf

24 levels in humans, and IL-4 promotes IgE and IgG1 Ab production against allergens in mice.

25 rmal growth factor receptor (EGFR)-targeting IgG1 Abs fail to trigger efficient CDC.

26 mmunized Atad5(+/m) mice had decreased serum IgG1 Abs, demonstrating a functional effect on class swi

27 in IgG1(+) memory B cells and virus-specific IgG1 Abs.

28 Moreover, polyclonal IgG or monoclonal IgG1 added to IgG-depleted PRP increased the lag time in

29 We constructed a humanized monoclonal IgG1 against human adenovirus type 5 (AdV5) and a panel

30 ct different RV strains, and serum levels of IgG1 against purified recombinant VP1 proteins from repr

31 Increases in RV-specific IgG1 against RV-A or against RV-A and RV-C were signific

32 Because IgG1 allotypes might have different half-lives, their in

33 netics of mAbs, the interaction of different IgG1 allotypes with FcRn was examined using cellular ass

34 ch FcgammaRIII on some other cell engaged by IgG1-amastigote immune complexes induces IL-10 from T ce

35 with RNAdjuvant significantly enhanced this IgG1 and additionally promoted the formation of IgG2b/c,

36 ration at previously intractable sites of an IgG1 and at multiple sites in the same polypeptide chain

37 ive autoantigen in fibrillary GN and suggest IgG1 and classic complement effector pathways as likely

38 ing epithelial cell line (T84) in which both IgG1 and Fc-fusions were transported in an FcRn-dependen

39 ed in a reduced frequency of Peyer's Patches IgG1 and germinal center B cells in addition to small bu

40 diminishes plasma levels of antigen-specific IgG1 and IgE antibodies, airway hyperreactivity, airway

41 y a partial CSR block, producing near normal IgG1 and IgE but substantially reduced IgG3, IgG2b, and

42 d significantly increased serum OVA-specific IgG1 and IgE in rested mice that previously developed mu

43 ized by Th1 and Th2/0 responses and enhanced IgG1 and IgE levels, which was delayed by wild-type regu

44 T-cell-derived IL-4/IL-13 was required for IgG1 and IgE production, recruitment of eosinophils and

45 liferation during activation of switching to IgG1 and IgE.

46 Th2 immunity and increased allergen-specific IgG1 and IgE.

47 b responses correlated with plasma levels of IgG1 and IgG2 anti-HIV-1 p24 and, notably, correlated in

48 ose given 2 doses of PsA-TT had the greatest IgG1 and IgG2 GMCs of 125.23 microg/mL and 36.12 microg/

49 Group A-specific IgG1 and IgG2 GMCs remained greater in the PsA-TT group

50 the geometric mean concentrations (GMCs) of IgG1 and IgG2 in the PsA-TT group were 21.73 microg/mL a

51 P. gingivalis IgG1 and IgG2 were analyzed.

52 While immunization typically stimulated IgG1 and IgG2, AIT is often associated with production o

53 h the VC2-EHV-1-gD vaccine stimulated robust IgG1 and IgG2a antibodies after three vaccinations (P <

54 ter membrane protein OmpD, which induce both IgG1 and IgG2a in mice, provide protection to S.

55 of Nur77-KO mice, as well as increased serum IgG1 and IgG2a levels.

56 sults were further potentiated by serum IgG, IgG1 and IgG2a titers.

57 lr/wild-type mice led to a decrease of serum IgG1 and IgG2c but not IgG3, as well as decreased IgM, a

58 igen-specific T cell responses and increased IgG1 and IgG2c compared with wild type controls.

59 owed significantly higher alpha-gal-specific IgG1 and IgG3 Ab than nonallergic individuals, whereas t

60 His brother with low-to-moderate-affinity IgG1 and IgG3 also later developed low-titer FVIII inhib

61 ord serum samples were assayed for levels of IgG1 and IgG3 specific for MSP119, MSP2 (both allelic fa

62 the V1V2 region of gp120, in particular the IgG1 and IgG3 subclass mediating antibody-dependent cell

63 the study, while production of cat-specific IgG1 and IgG3 was not stimulated by MAT-Feld1 ILIT.

64 ers >/=1:40, mostly low-to-moderate-affinity IgG1 and IgG3, and 1 had high-affinity IgG4 and later de

65 ased erythrocyte lysis was observed with the IgG1 and IgG3, respectively, but no increase with IgG2 a

66 Humoral immunity was dominated by IgG1 and IgG3, whereas the Th2-associated IgG4 isotype w

67 was mirrored by the presence of LTP-specific IgG1 and IgG3.

68 ification of allergen-specific serum IgE and IgG1 and of the mast cell protease MCPT1, as well as spl

69 fusion protein composed of the Fc region of IgG1 and the extracellular domain of CTLA4 (also known a

70 M sensitization, and their anti-Der p 1 IgE, IgG1 and total IgE responses were reduced by 80-90% comp

71 t Asn-77 (equivalent to Asn-297 in the Fc of IgG1) and Asn-236 (equivalent to Asn-563 in the tail pie

72 mice, produce transcripts that generate IgM, IgG1, and IgE in an alternative splice form bias hierarc

73 on resulted in higher serological total IgG, IgG1, and IgG2a anti-alpha-syn levels.

74 Peanut-specific serum IgE, IgG1, and IgG2a levels were measured by using ELISA, as

75 5-fold increases in F1-V-specific total IgG, IgG1, and IgG2c titers in immune sera by day 77, respect

76 tched" heavy and light chains were cloned as IgG1, and those of high affinity for specific SAEs, assa

77 tion and histamine predominance in mice with IgG1- and IgG2b-induced anaphylaxis correlated with the

78 ) 3F7.A10 to BALB/c mice with high titers of IgG1 anti-3F7.A10 led to glomerular deposits of IgG1/IgG

79 Clinical testing of a human IgG1 anti-CD27 Ab, varlilumab (clone 1F5), is ongoing in

80 mouse mast cell protease 1), increased serum IgG1 anti-EW and IgE levels, and increased IL-4 and IL-1

81 e-DNA subunit of chromatin, four elicited an IgG1 anti-mAb response and one mAb was nonimmunogenic.

82 SAP, we infused a fully humanized monoclonal IgG1 anti-SAP antibody.

83 that the titers of the total IgG and subtype IgG1 anti-SjHSP60 antibodies were positively correlated

84 ne mechanisms that involve allergen-specific IgG1 antibodies and plasma or regulatory T cell-derived

85 suggest that numerous therapeutic monoclonal IgG1 antibodies may be utilized in this platform, which

86 Therefore, we analyzed the two IgG1 antibodies, briakinumab and ustekinumab, that have

87 lected and used to construct isotype-matched IgG1 antibodies, which were then expressed in mammalian

88 d production of anti-trinitrophenyl chloride IgG1 antibodies.

89 et) oxidation on the biological functions of IgG1 antibodies.

90 cific immune response predominantly based on IgG1 antibodies.

91 e shown that a new CXCR4 receptor antagonist IgG1 antibody (PF-06747143) binds strongly to AML cell l

92 al antibody species: an IgG2 antibody and an IgG1 antibody conjugate.

93 r findings indicate that the SjHSP60 IgG and IgG1 antibody levels can be used as potential candidate

94 ositive regulatory T cells, and OVA-specific IgG1 antibody levels were only observed in mice undergoi

95 ate resolution (~1-3 nm) from 120 individual IgG1 antibody particles.

96 ed alphaSyn-specific T-helper (Th)1/Th17 and IgG1 antibody responses (up to a 3-fold increase) with M

97 The human IgG1 antibody subclass shows distinct properties compare

98 ave described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY pepti

99 ctionLess (SEFL) antibody was designed as an IgG1 antibody with a constant region that lacks the abil

100 Sandy-2 and a previously described rat IgG1 antibody, 5A8, also formed a pair suitable for the

101 human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic ur

102 molgus FcgammaRs compared with the wild-type IgG1 antibody.

103 structure of a homologous immunoglobulin G1 (IgG1) antibody (PDB: 1HZH ), the backbone amide of Ser23

104 ll as the largest protein attempted to date (IgG1-antibody).

105 and 87% for the heavy and light chain of the IgG1-antibody, respectively.

106 eviously, we developed the recombinant human IgG1 antimannan antibody M1g1.

107 oteome of fibrillary GN cases also contained IgG1 as the dominant Ig and proteins of the classic comp

108 t of peanut-specific immunoglobulins IgE and IgG1 as well as anaphylaxis while exogenous delivery of

109 tleneck, we fused GCSF with the Fc domain of IgG1 at the C terminus (GCSF-Fc) and with the maltose bi

110 trong Th2 cell responses, including dominant IgG1 autoantibodies, elevated serum IgE, increased Th2 c

111 ressed alloantibody production by alloprimed IgG1 B cells and delayed graft rejection in both low and

112 CNi to suppress CD8-mediated cytotoxicity of IgG1 B cells was evaluated in in vitro and in vivo cytot

113 mice adoptively transferred with alloprimed IgG1 B cells.

114 Here an attempt was made to engineer an IgG1-based scaffold lacking effector function but with s

115 ons and clinical efficacy of next-generation IgG1-based therapeutics.

116 structural information on full-length human IgG1 because of the challenges of crystallization.

117 We found that class-switching to IgG1 biased the fate choice made by B cells, favoring th

118 positively correlated with the magnitude of IgG1 binding, and IgG1 levels were associated with survi

119 FcgammaRIV and inhibitory FcgammaRIIB; mouse IgG1 binds only FcgammaRIII and FcgammaRIIB.

120 thod for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

121 ort the unexpected finding that mice lacking IgG1, but not IgG2a, are substantially less protected af

122 Ab comprised of a TLQ mutant and a wild-type IgG1 can be efficiently separated from contaminating par

123 Thus, the Th2-associated isotype IgG1 can play a role in protection against Th1-associate

124 G clones, including a non-natural bispecific IgG1 candidate, targeting Pseudomonas aeruginosa.

125 affinity IgE is produced by the switching of IgG1 cells to IgE.

126 ame phenotypic stages were also observed for IgG1(+) cells.

127 TCR alpha/beta constant domain pair and the IgG1 CH3 homodimer was evidenced by X-ray crystallograph

128 we found that they successfully drive human IgG1 CH3 or IgM CH4 heterodimerization to levels similar

129 ated interfaces from human IgA CH3, IgD CH3, IgG1 CH3, IgM CH4, T-cell receptor (TCR) alpha/beta, and

130 rmal numbers with Stat3-deficient TFH cells, IgG1 class switching was greatly increased.

131 a previously unappreciated role for Flt3 in IgG1 class-switch recombination (CSR) and production.

132 We found that IgG1-coated viral particles were neutralized via TRIM21,

133 The data show elevated specific IgE and IgG1 concentrations in the blood of OVA-sensitized Cyp27

134 tion of BM cells from PF-06747143-treated or IgG1 control-treated animals showed that leukemic progen

135 s 24 h after a single dose of conatumumab or IgG1 control.

136 s 24 h after a single dose of conatumumab or IgG1 control.

137 ant IgG3 anti-V2 MAbs were compared to their IgG1 counterparts.

138 t3 ligand-deficient mice results in impaired IgG1 CSR and accumulation of IgM-secreting plasma cells.

139 Here we show that IgG1-deficient (gamma1(-)) mice, immunized with a potent

140 The decreased protection in IgG1-deficient mice correlates with less efficient bacte

141 IgG1-deficient mice produce more porin-specific IgG2a, r

142 mpanied by high levels of alpha-gal-specific IgG1 devoid of IgE-blocking activity.

143 sition 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content

144 Analysis of the IgG1 drug conjugate further exemplified the advantages o

145 Our molecular models for human IgG1 explain its immune activities, and we discuss its s

146 that secondary isotype switching of mutated IgG1-expressing B cells is the primary source of IgE in

147 f the agonism of the anti-OX40 antibody with IgG1 Fc but not with the silent IgG2sigma Fc.

148 n antibodies attached via linkers to a human IgG1 Fc domain.

149 eries of sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C'E loop and the C

150 e truncated glycoforms, suggesting a role of IgG1 Fc N-glycan in optimizing the interface with the Fc

151 domain antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb.

152 glycans can modulate the binding affinity of IgG1 Fc to Fc gamma receptors, but it is unclear how the

153 ly, we demonstrated that aglycosylated human IgG1 Fc variants can engage the human FcgammaRII class o

154 at Asn-297 on the structure and function of IgG1-Fc is well documented; however, whether the N-linke

155 The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (h

156 e retaining the functional properties of the IgG1-Fc.

157 That IgG1 galactosylation is a predictor of immune activation

158 at asthmatic children seemed to have reduced IgG1 galactosylation levels as well.

159 High IgG1 galactosylation levels correlated with low total Ig

160 This indicates that IgG1 galactosylation levels could be used as a biomarker

161 IgG1 galactosylation levels were generally higher in mor

162 tions was a significant predictor of reduced IgG1 galactosylation levels.

163 ng NK cell expression of CD32B or CD32C, and IgG1 H chain (IGHG1) and kappa-chain (IGKC) polymorphism

164 (GM) 3/17 variants in the immunoglobulin G1 (IgG1) heavy chain constant region, virus neutralization,

165 of the constant Fc part of monoclonal human IgG1 (hIgG1) Abs is an approach to improve effector func

166 reases the ligand binding affinity for human IgG1 (hIgG1) but increases it for murine IgG2a (mIgG2a).

167 B cells and promoted the production of IgM, IgG1, IgA, and IgE by these cells in vitro.

168 The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structu

169 females had elevated levels of Env-specific IgG1, IgG2, and IgG3 Abs compared with males.

170 ecretion of the inflammatory factors such as IgG1, IgG2, IgM, IL-6 and PMPhi phagocytosis, stimulatio

171 eneral phenotype (generating 2.5-fold higher IgG1/IgG2 levels).

172 The IgG1:IgG2 mean ratio decreased following successive vacc

173 , and demonstrated a significant increase in IgG1:IgG2 mean ratio, indicative of the T-cell-dependent

174 rine bsAbs for all subclasses studied (mouse IgG1, IgG2a and IgG2b; rat IgG1, IgG2a, IgG2b, and IgG2c

175 ization of Salmonella with O:4-specific IgA, IgG1, IgG2a, and IgG2b, but not IgM, resulted in cell-de

176 es studied (mouse IgG1, IgG2a and IgG2b; rat IgG1, IgG2a, IgG2b, and IgG2c).

177 Mice were sensitized with IgG1, IgG2a, or IgG2b anti-trinitrophenyl mAbs and chall

178 mine which pathways control the induction of IgG1-, IgG2a-, and IgG2b-dependent passive systemic anap

179 1 anti-3F7.A10 led to glomerular deposits of IgG1/IgG2a complexes.

180 Frequencies of isotype switching to IgG1, IgG2b, IgG2c, and IgG3 were the same as C57BL/6 co

181 Of these women, 71.4% were IgG1+IgG3+, consistent with more recent chlamydia resolu

182 the C1q binding site or via generation of an IgG1/IgG3 chimera.

183 cellular memory response in combination with IgG1/IgG3-dominated humoral immunity that increase with

184 Concentrations of allergen-specific IgE, IgG1, IgG4 and IgA to seven Bet v 1-related food allerge

185 ergy and increased or reduced levels of IgE, IgG1, IgG4 or IgA specific to most Bet v 1-related aller

186 Specific and total IgG1, IgG4, IgA, and IgE from plasma as well as culture

187 ived IgG sequence repertoires revealed lower IgG1/IgGtotal representation compared with antibodies fr

188 on and found significantly increased IgE and IgG1 in DeltawaaP mutant-infected mice.

189 iximab is a better competitor for endogenous IgG1 in G1m3,-1 allotype-bearing patients.

190 support a role for eliciting ADCC-mediating IgG1 in HIV vaccines.

191 IgG2a (IgG1 in humans) can prevent acute infections, and T-bet

192 d the production of antigen-specific IgE and IgG1 in serum.

193 These effector molecules bind to IgG1 in the lower hinge-CH2 region, structurally distant

194 races of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.

195 B cells to IgE synthesis, most likely via an IgG1(+) intermediate.

196 We further demonstrate that GP-specific IgG1 is by far the seroprevalent subclass that retained

197 n 4 (IL-4), hence class switching to IgE and IgG1, is not fully understood.

198 Tildrakizumab is a high-affinity, humanised, IgG1 kappa antibody targeting interleukin 23 p19 that re

199 herapeutic monoclonal antibody (sifalimumab; IgG1/kappa).

200 significant decrease in peanut-specific IgE/IgG1 levels and an increase in peanut-specific IgG2a lev

201 reas IgA was strongly induced (20-fold), and IgG1 levels remained unchanged.

202 ly stimulated both the humoral (>32 times of IgG1 levels vs alum) and the cell-mediated immune respon

203 ated with the magnitude of IgG1 binding, and IgG1 levels were associated with survival in infected in

204 ivity, total cell count and specific IgE and IgG1 levels were lower in SAM11-administered mice.

205 nificantly increased IgG2a without affecting IgG1 levels.

206 ne responses and serum allergen-specific IgE/IgG1 levels.

207 neric platform for production of tetravalent IgG1-like chimeric bispecific Abs.

208 investigate serum anti-CT immunoglobulin G1 (IgG1; long-lived response) and immunoglobulin G3 (IgG3;

209 impurities of an anti-Clostridium difficile IgG1 mAb drug substance were profiled by cation-exchange

210 region and His231 in the hinge region of the IgG1 mAb heavy chain.

211 clotron mass spectrometer to characterize an IgG1 mAb molecule conjugated with biotin via native lysi

212 N-linked glycan heterogeneity present on an IgG1 mAb molecule containing two distinct N-linked glyco

213 The structural assessment of Rituximab, an IgG1 mAb, was investigated with deep-ultraviolet resonan

214 the Fc regions of fully human and humanized IgG1 mAbs as well as of Fc-fusion proteins.

215 ominant ADCP activity compared to a panel of IgG1 MAbs.

216 ious role in malignant melanoma, by impeding IgG1-mediated anti-tumor immunity.

217 ttenuation of inflammation through promoting IgG1-mediated damping of the FcepsilonRI-dependent acute

218 re we investigate the function of subsets of IgG1 memory B cells in IgE production and find that two

219 generated via class-switch recombination in IgG1 memory B cells without additional somatic hypermuta

220 IgE production and find that two subsets of IgG1 memory B cells, CD80(+)CD73(+) and CD80(-)CD73(-),

221 hereas there was a corresponding increase in IgG1(+) memory B cells and virus-specific IgG1 Abs.

222 that IgG Fc sialylation of human monoclonal IgG1 molecules impairs their efficacy to induce compleme

223 een demonstrated to allow the preparation of IgG1 monoclonal antibodies with lower fucosylation level

224 IgG1 monoclonal antibodies with reduced glycan fucosylat

225 An IgG1 monoclonal antibody (mAb) purified by Protein A col

226 An anti-SsE IgG1 monoclonal antibody (MAb), 2B11, neutralized the PA

227 ntibody-drug conjugate (ADC), composed of an IgG1 monoclonal antibody (mAb), mertansine drug (DM1), a

228 high-molecular weight (HMW) fractions of an IgG1 monoclonal antibody (mAb).

229 Here, we show that targeting EGFRt with the IgG1 monoclonal antibody cetuximab eliminates CD19 CAR T

230 pment of REGN421 (enoticumab), a fully human IgG1 monoclonal antibody that binds human Dll4 with sub-

231 Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting

232 mpared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by

233 11B6 is an IgG1 monoclonal antibody that is specific to free human

234 Ramucirumab (named RamAb), a fully humanized IgG1 monoclonal antibody, was conjugated to 2-S-(4-isoth

235 ice, we demonstrate that anti-tumor human (h)IgG1 must engage hFcgammaRIIIA on macrophages to mediate

236 One of them, a mouse IgG1 named Sandy-2, prevented the binding of BAFF to all

237 ated SEE-induced basophil degranulation, and IgG1 or antigen-binding fragments of each anti-SEE enhan

238 mpared with wild-type mice, but not those of IgG1 or IgA.

239 psilon/epsilon mice, which initially produce IgG1 or IgE from their respective native genomic configu

240 d on identical murine backbones as either an IgG1 or IgG2a subclass and evaluated for binding to mult

241 sive immunization models by antigen-specific IgG1; other isotypes are less potent at preventing disea

242 however, pHF-OS reduced cow's milk-specific IgG1 (P < 0.0001) and increased regulatory T-cell and pl

243 te IgG1 (P = .027) and IgG3 (P = .025), AMA1 IgG1 (P = .001), and EBA175 IgG3 (P = .001).

244 IgG1 (P = .029), AMA1 IgG (P = .002), lysate IgG1 (P = .001), and MSP1 IgG3 (P = .01).

245 HIV was associated with reduced CMR of MSP1 IgG1 (P = .022) and IgG3 (P = .023), lysate IgG1 (P = .0

246 IgG1 (P = .022) and IgG3 (P = .023), lysate IgG1 (P = .027) and IgG3 (P = .025), AMA1 IgG1 (P = .001

247 ith reduced CMR of EBA175 IgG (P = .014) and IgG1 (P = .029), AMA1 IgG (P = .002), lysate IgG1 (P = .

248 fic germinal centers (23.3 days), IgE(+) and IgG1(+) PCs (60 and 234.4 days, respectively), and clini

249 nalysis indicates that high affinity IgE and IgG1 plasma cells differentiate from rare CD80(+)CD73(+)

250 20 million cells/mL) perfusion culture of an IgG1-producing Chinese hamster ovary (CHO) cell line for

251 te Freund's adjuvant, enhanced IgG2a but not IgG1 production was also observed, and CD4+ FoxP3+ T cel

252 germ-line transcripts, resulting in impaired IgG1 production.

253 ression modeling predicted that CSP-specific IgG1 promote OPA, and that CSP-specific IgG4 interferes

254 molecular weight fraction, induced specific IgG1 , pulmonary infiltration with inflammatory cells, a

255 reliable and clog-free cell retention, high IgG1 recovery (>99%) and cell viability (>97%).

256 Anti-EMP2 IgG1 reduced the expression and activity of ALDH and cor

257 that the total IgG response switched from an IgG1 response to an IgG3 response after infection with L

258 ent MDP show a strong Th2-bias (dominance of IgG1 response).

259 er PsA-TT or PsACWY elicited a predominantly IgG1 response.

260 or germinal center formation, and long-lived IgG1 responses of unaltered affinity developed in mice l

261 fic IgE responses against allergens, whereas IgG1 responses to allergens remain unaffected.

262 In vivo OVA-specific IgG1 responses, after subcutaneous prime/boosts in mice,

263 parately, 1Z105 induces rapid Th2-associated IgG1 responses, and 1V270 potently generates Th1 cellula

264 er IL-4 production with increased anti-viral IgG1 responses.

265 Furthermore, deglycosylation of IgG1 resulted in a 40-fold loss in FcgammaRI binding, de

266 ased on a recently described antibody mutant IgG1-RGY that forms hexamers and activates complement in

267 The fully saturated IgG1-RGY-antigen complexes displayed a stoichiometry of

268 ines restricting production of afucosylated, IgG1 RNNIg during infection may prevent ADE of DENV dise

269 r than or equivalent to that of the parental IgG1 scaffold.

270 Accordingly, more OVA-specific IgG1-secreting cells are present in spleen and fewer in

271 ently increased specific serum IgA, IgE, and IgG1 serum levels (2.0- and 8.9-fold).

272 maRI reporter response and GP-specific total IgG1 subclass correlated in the studied group of Ebola s

273 s CD4(+) Th cell-dependent, dominated by the IgG1 subclass, and Id specific.

274 e a wealth of structural information for the IgG1 subclass, including complexes with Fcgamma receptor

275 ammaRIIIA due to afucosylated Fc glycans and IgG1 subclass.

276 n led to the production of IgG mainly of the IgG1 subtype.

277 te-phase allergic response, IL-10 is a known IgG1 switch factor.

278 Yet IgG1, the predominant murine serum Ig isotype, cannot ac

279 dependent bispecific (TDB) full-length human IgG1 therapeutic antibody targeting CLL-1 that could pot

280 cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor forma

281 that correlated with increased SEA-specific IgG1 titers.

282 The binding of human IgG1 to human Fc gamma receptors (hFcgammaRs) is highly

283 creased from baseline in conatumumab- versus IgG1-treated COLO205 and HT29 tumor-bearing mice (P = 0.

284 7-fold from baseline in conatumumab- versus IgG1-treated control mice (P < 0.001), in good correlati

285 7-fold from baseline in conatumumab- versus IgG1-treated control mice (P < 0.001), in good correlati

286 RNNIg enriched for afucosylated IgG1 triggered platelet reduction in vivo and was a sign

287 Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (

288 unit vaccine induced moderate virus-specific IgG1, vaccination together with RNAdjuvant significantly

289 th docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient popul

290 At 29 dpv, a significant switch to IgG1 was clear in prescapular LN, while FMDV-specific AS

291 ion, and cytokine production, but IgE or HDM IgG1 was not induced.

292 An increase in RV-specific IgG1 was seen in 61% (n = 73) of the children at follow-

293 On day 14, OVA-specific IgG2a and IgG1 were measured in the serum.

294 in ASC numbers and rapid isotype switches to IgG1 were observed, particularly in LN-draining virus re

295 IgG2a, OVA-specific IgG2a, and OVA-specific IgG1 were reduced in the setting of infection.

296 ation, and immunoglobulin class switching to IgG1, were enhanced in Batf3(-/-) mice responding to hel

297 m-precipitated proteins and helminths induce IgG1, whereas Th1 Ags, such as Salmonella Typhimurium, p

298 nd Q311R or "TLQ") in the Fc region of human IgG1 which disrupt interaction with protein A while enha

299 uction, and an increase in total IgE and HDM IgG1, while LT-HDM was not able to do so.

300 and demonstrate a failure to initiate CSR to IgG1 with low expression of gamma1 germ-line transcripts